Cynvenio Announces New LiquidBiopsy® Test for PD-L2 Expression

Company launches the first commercially available liquid biopsy test for measuring PD-L2 expression in tumor cells. The test provides clinical researchers the ability to study how an individual’s expression of PD-L2 relates to checkpoint inhibitors response.   

WESTLAKE VILLAGE, CA – September 6, 2017 – Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, today announced the launch of its PD-L2 expression test. The first of its kind, the new blood test enables highly sensitive and specific profiling and monitoring of PD-L2 expression in cancer cells recovered from a simple blood draw.

Cynvenio’s PD-L2 test is the first commercial RUO test that measures PD-L2 expression in circulating tumor cells (CTCs).  Recent study data have shown that PD-L2 expression provides valuable information beyond PD-L1 positivity in predicting clinical response to pembrolizumab (Keytruda®) in head and neck squamous cell carcinoma (HNSCC)✝.

“The PD-1 pathway is an important therapeutic target in various cancer types,” commented Paul Dempsey, Ph.D., Chief Scientific Officer at Cynvenio Biosystems. “Our new PD-L2 assay enables researchers to more fully understand another target and another regulator of immune evasion. This may contribute to determining which patients may better respond to checkpoint inhibition.”

For additional information or to order the test, please contact Cynvenio at 888-885-1172.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit www.cynvenio.comwww.clearidmonitoring.com, and www.liquidbiopsy.com.

Yearley et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017 Jun 15;23(12):3158-3167.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.